Targeted Radiosensitization in Prostate Cancer

Author(s): Veerander P.S. Ghotra, Albert A. Geldof, Erik H.J. Danen

Journal Name: Current Pharmaceutical Design

Volume 19 , Issue 15 , 2013

Become EABM
Become Reviewer
Call for Editor


Radiotherapy is one of the treatment options for locally or regionally advanced prostate cancer, but radioresistance of prostate cancer cells is a practical limitation of radiotherapy. The identification of molecular targets of radioresistance in prostate cancer is important to improve therapeutic intervention. The aim of this review is to give more biological insight into some well known processes involved in radioresistance of prostate cancer especially Apoptotic pathway; DNA damage response; and NF-κB(nuclear factor kappalight- chain-enhancer of activated B cells) signaling pathway. This review integrates salient, published, research findings with underlying molecular mechanisms, preclinical efficacy, and potential clinical applications of combining radiotherapy with these molecular targeted agents for the treatment of prostate cancer.

Keywords: Prostate cancer, radiotherapy, radiosensitization

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Published on: 20 March, 2013
Page: [2819 - 2828]
Pages: 10
DOI: 10.2174/1381612811319150017
Price: $65

Article Metrics

PDF: 20